BioCentury on BioBusiness,
Emerging Company Profile
Piqur developing next-generation dual PI3K/mTOR inhibitors optimized for cancer
Related tables, figures and sidebars
Piqur: Optimizing dual inhibition
Monday, June 4, 2012
Therapeutics Inc. has developed a dual inhibitor of PI3K and mTOR that
it says could treat solid tumors more effectively than dual PI3K/mTOR inhibitors
in the clinic because it hits both targets with potencies that are optimized to
enhance the overall inhibitory effect on PI3K/mTOR signaling.
Signaling by phosphoinositide
3-kinase (PI3K) and mammalian target of rapamycin (mTOR; FRAP; RAFT1) promotes
cell proliferation and survival. Because the PI3K/mTOR pathway is
over-activated in cancer, the original rationale behind dual PI3K/mTOR
inhibition was straightforward: hit both targets with equal potency and block
signaling through the pathway.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]